---
schema_version: "secwatch.filing_event.v1"
accession: "0001641172-25-000987"
form_type: "8-K"
ticker: "WGRX"
cik: "0002030763"
company_name: "Wellgistics Health, Inc."
filed_at: "2025-03-27T23:59:59+00:00"
generated_at: "2026-05-24T04:24:41.768069+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Wellgistics grants 19.8M shares of restricted stock; reports pro forma 2024 revenue of $45.7M

## Summary
- Granted 19,764,108 restricted shares under the 2023 Equity Plan, including 9M to CEO vesting on financial metrics for FY2025-2027.
- Pro forma consolidated net sales for 2024 were $45.7M, a 33% increase over 2023, assuming recent acquisitions occurred Jan 1, 2023.
- Launched EinsteinRx, an AI-driven decision support software integrated into the Wellgistics Hub prescription platform.
- Aims to onboard 5,000 pharmacies by mid-2026 and grow active patient base 10x by year-end.
- Plans multiple tech-driven acquisitions and predictive care AI for customer service and benefits verification.

## SEC filing metadata
- accession: 0001641172-25-000987
- form_type: 8-K
- ticker: WGRX
- cik: 0002030763
- company_name: Wellgistics Health, Inc.
- filed_at: 2025-03-27T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 3.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/2030763/000164117225000987/0001641172-25-000987-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/2030763/000164117225000987/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001641172-25-000987
- JSON: https://secwatch.observer/filing/0001641172-25-000987.json
- Plain text: https://secwatch.observer/filing/0001641172-25-000987.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.